Caris Life Sciences, Inc.
HealthcareNASDAQ:CAI · NASDAQ Global Select
-$0.02 today
Vol 1.96M · Avg 2.67M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$907.3M of revenue converted into $34.0M of net income for the selected period. Gross margin is 67.9% and net margin is -0.2%, showing how much revenue survives after costs and taxes. EPS is $-1.51, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $812.0M +97.0% | $412.3M +34.7% | $306.1M +18.4% | $258.5M -12.1% | $294.0M | $921.6M | $731.2M | $843.2M |
| Cost of Revenue | $272.9M +16.9% | $233.5M +7.7% | $216.8M +21.5% | $178.5M +62.5% | $109.9M | $804.0M | $882.4M | $1.3B |
| Gross Profit | $539.2M +201.6% | $178.8M +100.2% | $89.3M +11.6% | $80.0M -56.5% | $184.2M | $7.6B | $6.2B | $4.9B |
| Gross Margin | 66.4% +23.0pp | 43.4% +14.2pp | 29.2% -1.8pp | 31.0% -31.7pp | 62.6% | 28.9% | 38.3% | 12.3% |
| Research & Development | $45.3M -60.2% | $113.9M -2.5% | $116.9M +15.4% | $101.3M | $0 | $1.3B | $490.4M | $1.1B |
| Selling, General & Admin | $392.5M +21.9% | $321.9M +10.4% | $291.5M -1.0% | $294.5M +978.3% | $27.3M | $923.0M | -$1.5B | $732.6M |
| Operating Expenses | $494.1M +13.3% | $435.9M +6.6% | $408.9M +3.3% | $395.8M +778.1% | $45.1M | $7.0B | $8.7B | $7.3B |
| Depreciation & Amortization | $22.6M -53.8% | $48.9M -0.2% | $49.0M +1.6% | $48.3M -56.4% | $110.7M | $1.2B | $631.8M | $1.5B |
| EBITDA | $11.4M +106.2% | -$183.0M +29.9% | -$260.8M -6.1% | -$245.9M -196.6% | $254.5M | $6.8B | $9.3B | $11.9B |
| EBITDA Margin | 1.4% +45.8pp | -44.4% +40.8pp | -85.2% +9.9pp | -95.1% -181.7pp | 86.5% | 46.3% | 42.0% | 37.7% |
| Operating Income | $45.1M +117.5% | -$257.1M +19.5% | -$319.6M -1.2% | -$315.8M -327.0% | $139.1M | $14.0B | -$15.7B | $14.3B |
| Operating Margin | 5.6% +67.9pp | -62.4% +42.0pp | -104.4% +17.8pp | -122.2% -169.5pp | 47.3% | 24.1% | 22.0% | 29.5% |
| Interest Income | $16.5M +131.6% | $7.1M -36.7% | $11.3M +1088.8% | $947.0K | $0 | -$1.6B | $405.0M | $561.8M |
| Interest Expense | $56.9M +13.6% | $50.0M +58.3% | $31.6M +18.5% | $26.7M -56.7% | $61.6M | $1.0B | $1.2B | $1.3B |
| Other Income / Expenses | -$113.2M -357.0% | -$24.8M -13.3% | -$21.9M -331.2% | -$5.1M +95.4% | -$109.6M | $1.4B | $1.2B | $1.1B |
| Income Before Tax | -$68.1M +75.8% | -$281.9M +17.4% | -$341.4M -6.4% | -$320.8M -1186.3% | $29.5M | $4.9B | $3.6B | $5.3B |
| Pre-Tax Margin | -8.4% +60.0pp | -68.4% +43.2pp | -111.5% +12.6pp | -124.1% -134.2pp | 10.0% | 18.7% | 26.2% | 24.1% |
| Income Tax Expense | $469.9M | $0 | $0 | $0 -100.0% | $1.8M | -$1.6B | $745.2M | $1.0B |
| Net Income | -$538.0M -90.8% | -$281.9M +17.4% | -$341.4M -6.4% | -$320.8M -1256.8% | $27.7M | $4.8B | $4.7B | -$15.5B |
| Net Margin | -66.2% +2.1pp | -68.4% +43.2pp | -111.5% +12.6pp | -124.1% -133.6pp | 9.4% | 17.5% | 22.5% | 27.5% |
| EPS (Basic) | -$2 +29.6% | -$3 -48.4% | -$2 -15.9% | -$2 -201.3% | $2 | $703.2M | $1.3B | $512.8M |
| EPS (Diluted) | -$2 +29.6% | -$3 -48.4% | -$2 -15.9% | -$2 -201.3% | $2 | $609.4M | $452.6M | $598.2M |
| Weighted Avg Shares | $1.7B +556.6% | $254.7M +0.0% | $254.7M -0.0% | $254.8M +1319.5% | $17.9M | $925.8M | $1.1B | $1.3B |
| Weighted Avg Shares (Diluted) | $1.7B +556.6% | $254.7M +0.0% | $254.7M -0.0% | $254.8M +1319.5% | $17.9M | $924.4M | $678.0M | -$1.5B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.44B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.04B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.92B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.75B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Merus N.V.
MRUS
$6.83B
Abivax S.A.
NASDAQ:ABVX
$6.37B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.05B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.40M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CAI generate?
Caris Life Sciences, Inc. (CAI) reported $812.03M of revenue in fiscal 2025.
Is CAI profitable?
Caris Life Sciences, Inc. (CAI) reported -$537,957,000.00 of net income, with a net margin of -66.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.